de Oliveira Machado A L, Adams E F, Schott W, Nomikos P, Fahlbusch R, Buchfelder M
Department of Neurosurgery, University of Erlangen-Nürnberg, Erlangen, Germany.
Exp Clin Endocrinol Diabetes. 2005 Jun;113(6):344-9. doi: 10.1055/s-2005-865613.
In this study, the central technique of in vitro culture has been used to further investigate whether LH/FSH-expressing, but clinically "functionless" pituitary adenomas are gonadotropinomas or whether their hormone secretion is due to transdifferentiation events. 664 "functionless" pituitary adenomas were examined for hormone secretion by in vitro culture and for hormone content by immunostaining. The results were correlated with the clinical findings. 40 % of the tumours (n = 263) secreted at least one of the gonadotropins alone, 8 % (n = 53) exhibited various patterns of anterior pituitary hormones, whilst the remaining 52 % of tumours were not associated with any hormone. In the secretory tumours, immunostaining revealed only a few scattered hormone-containing cells (5 to 15 %). Mild hyperprolactinaemia was observed in some cases, presumably because of pressure effects of the tumours. The majority of the patients suffered clear cut hypopituitarism (p < 0.05). Pre-operatively, gonadotropin hypersecretion was observed in 3 cases, but only one of these secreted hormones in culture. Interestingly, a higher proportion of tumours removed from patients with hypopituitarism showed secretory activity in vitro than those tumours removed from patients showing no hormonal dysfunction or hyperprolactinaemia. We conclude that the term "gonadotropinoma" to describe functionless pituitary tumours associated with LH and/or FSH secretion is a misnomer, because the presence of LH and/or FSH confirmed by in vitro methods in the present series is a result of only a few scattered cells. We suggest that primary pituitary tumour cells differentiate into a secretory type (transdifferentiation), possibly in response to altered serum hormone levels such as decreased steroids. Further work is required to identify the factors which trigger the altered cells' characteristics.
在本研究中,采用体外培养的核心技术进一步研究表达促黄体生成素/促卵泡生成素但临床上“无功能”的垂体腺瘤是否为促性腺激素瘤,或者其激素分泌是否归因于转分化事件。通过体外培养检测了664例“无功能”垂体腺瘤的激素分泌情况,并通过免疫染色检测了激素含量。将结果与临床发现进行了关联分析。40%的肿瘤(n = 263)仅分泌至少一种促性腺激素,8%(n = 53)表现出各种垂体前叶激素分泌模式,而其余52%的肿瘤与任何激素均无关联。在分泌性肿瘤中,免疫染色仅显示少数散在的含激素细胞(5%至15%)。在某些病例中观察到轻度高泌乳素血症,推测是由于肿瘤的压迫作用。大多数患者出现明显的垂体功能减退(p < 0.05)。术前,在3例患者中观察到促性腺激素分泌过多,但其中只有1例在培养中分泌激素。有趣的是,与无激素功能障碍或高泌乳素血症的患者相比,垂体功能减退患者切除的肿瘤在体外显示分泌活性的比例更高。我们得出结论,用“促性腺激素瘤”来描述与促黄体生成素和/或促卵泡生成素分泌相关的无功能垂体肿瘤是一个误称,因为在本系列研究中,体外方法证实的促黄体生成素和/或促卵泡生成素的存在仅是少数散在细胞的结果。我们认为,原发性垂体肿瘤细胞可能会分化为分泌型(转分化),这可能是对血清激素水平改变(如类固醇减少)的反应。需要进一步开展工作来确定触发细胞特性改变的因素。